Mesoblast rallied 8.5 per cent as it reported $US35.1 million in gross revenue from Ryoncil sales in the December quarter, up 60 per cent on the prior period.
You're not a member! Trial today
Mesoblast made its first commercial sales of Ryoncil in March last year after the US Food and Drug Administration approved the therapy to treat children for complications that could occur during bone marrow transplants. The company on Friday reported $US35.1 million ($52.4 million) in sales of Ryoncil in the three months to December 31. This was a 60 per cent jump from the September quarter.
